Drugs / Acarizax
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05113394 | Feb 2027 → Feb 2028 | allergic disease, asthma | Boston Children's Hospital | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07013123 | Jul 2025 → Aug 2029 expected | asthma, house allergic alveolitis | University Hospital, Montpellier | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04100902 Comparator | Jan 2020 → Feb 2022 | allergic asthma | Bispebjerg Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06509243 Comparator | Feb 2023 → Mar 2024 | atopic eczema | Medical University of Silesia | Completed | No outcome recorded |
Press releases naming this drug 13 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-03-07 | ALK-Abelló A/S | ACARIZAX® approved in Canada for treatment of young children alk.net ↗ |
| 2025-02-27 | ALK-Abelló A/S | FDA approves ODACTRA® for the treatment of house dust mite allergy in young children alk.net ↗ |
| 2025-01-30 | ALK-Abelló A/S | ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system alk.net ↗ |
| 2024-12-12 | ALK-Abelló A/S | ACARIZAX® approved in Europe for treatment of young children alk.net ↗ |
| 2017-11-30 | ALK-Abelló A/S | ALK secures pricing and reimbursement for ACARIZAX® in France alk.net ↗ |
| 2017-08-21 | ALK-Abelló A/S | ALK to accelerate launches of ODACTRA™ in the USA / ACARIZAX® in Canada alk.net ↗ |
| 2017-05-04 | ALK-Abelló A/S | ALK's HDM SLIT-tablet, ACARIZAX®, approved in Canada alk.net ↗ |
| 2017-04-16 | ALK-Abelló A/S | ACARIZAX® approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis alk.net ↗ |
| 2017-03-01 | ALK-Abelló A/S | ALK announces FDA approval for its house dust mite sublingual allergy immunotherapy tablet (ACARIZAX® in Europe) alk.net ↗ |
| 2017-02-27 | ALK-Abelló A/S | ALK’s ACARIZAX® data results in significant change to the GINA asthma management strategy: Sublingual allergy immunotherapy (SLIT) recommended as a treatment option in patients with house dust mite allergic asthma alk.net ↗ |
| 2016-04-27 | ALK-Abelló A/S | Journal of the American Medical Association publishes Phase III data from allergic asthma trial with ALK's house dust mite SLIT-tablet, ACARIZAX® alk.net ↗ |
| 2016-01-27 | ALK-Abelló A/S | Marketing authorisation for ACARIZAX® issued in France alk.net ↗ |
| 2015-12-09 | ALK-Abelló A/S | New product product (ACARIZAX®) for for treatment of house dust mite allergic rhinitis and asthma obtains reimbursement in Denmark alk.net ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACARIZAX | “HDM-SLIT tablet (Odactra®/Acarizax®) is a rapidly dissolving, freeze-dried, oral lyophilizate for oromucosal treatment, which contains a 1:1 mixture of two allergen extracts...” NCT05113394 ↗3“The patients have received SLIT-HDM (ACARIZAX, ALk Abello, Denmark) with 12 SQ-HDMs of a standardized allergen extract of the house dust mites Dermatophagoides pteronyssinus...” NCT06509243 ↗ |
| Known as | ODACTRA | “HDM-SLIT tablet (Odactra®/Acarizax®) is a rapidly dissolving, freeze-dried, oral lyophilizate for oromucosal treatment, which contains a 1:1 mixture of two allergen extracts...” NCT05113394 ↗ |
| Modality | Other / unclassified | “sublingual allergen immunotherapy (Acarizax)” NCT06509243 ↗ |
| Route | Other | “placed under the tongue” NCT06509243 ↗ |